Literature DB >> 2245252

Immunoregulatory cell dysfunction in chronic B-cell leukemias.

S L Zaknoen1, N E Kay.   

Abstract

Chronic B-cell malignancies are routinely characterized as B-cell clonal diseases that have signs and symptoms primarily related to the continuing expansion of these cells. This review discusses chronic lymphocytic leukemia, multiple myeloma and hairy cell leukemia from the perspective of secondary abnormalities in non-malignant cells. Thus, our main purpose is to elaborate on the alterations/abnormalities of the immunoregulatory (IR) cells in these diseases and focus on the qualitative and quantitative aspects of T-cells, natural killer (NK) cells and monocytes. The relevance of the IR-cell changes to the basic disease process and their complications are emphasized.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2245252     DOI: 10.1016/0268-960x(90)90044-s

Source DB:  PubMed          Journal:  Blood Rev        ISSN: 0268-960X            Impact factor:   8.250


  8 in total

1.  Expansion of CD4+ T cells with a cytotoxic phenotype in patients with B-chronic lymphocytic leukaemia (B-CLL).

Authors:  N Porakishvili; T Roschupkina; T Kalber; A P Jewell; K Patterson; K Yong; P M Lydyard
Journal:  Clin Exp Immunol       Date:  2001-10       Impact factor: 4.330

2.  Reduced frequency of NKT-like cells in patients with progressive chronic lymphocytic leukemia.

Authors:  Farhad Jadidi-Niaragh; Mahmood Jeddi-Tehrani; Bita Ansaripour; Seyed Mohsen Razavi; Ramazan Ali Sharifian; Fazel Shokri
Journal:  Med Oncol       Date:  2012-06-06       Impact factor: 3.064

3.  Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia (B-CLL): comparison of indolent and progressive disease.

Authors:  Shahryar Kiaii; Aniruddha Choudhury; Fariba Mozaffari; Eva Kimby; Anders Osterborg; Håkan Mellstedt
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

Review 4.  New treatments for chronic lymphocytic leukemia.

Authors:  Asher A Chanan-Khan
Journal:  Curr Oncol Rep       Date:  2007-09       Impact factor: 5.075

5.  Tumoricidal effects of activated macrophages in a mouse model of chronic lymphocytic leukemia.

Authors:  Qing-Li Wu; Ilia N Buhtoiarov; Paul M Sondel; Alexander L Rakhmilevich; Erik A Ranheim
Journal:  J Immunol       Date:  2009-06-01       Impact factor: 5.422

Review 6.  Regulatory T cells in chronic lymphocytic leukemia: implication for immunotherapeutic interventions.

Authors:  Farhad Jadidi-Niaragh; Ghasem Ghalamfarsa; Mehdi Yousefi; Mina Hajifaraj Tabrizi; Fazel Shokri
Journal:  Tumour Biol       Date:  2013-05-17

7.  Natural-killer-stimulatory effect of combined low-dose interleukin-2 and interferon beta in hairy-cell leukemia patients.

Authors:  A M Liberati; V De Angelis; M Fizzotti; M Schippa; M Cecchini; D Adiuto; F Di Clemente; L Palmisano; E Micozzi; M Zuccaccia
Journal:  Cancer Immunol Immunother       Date:  1994-05       Impact factor: 6.968

8.  Transforming growth factor beta as endogenous growth inhibitor of chronic lymphocytic leukemia B cells.

Authors:  M Lotz; E Ranheim; T J Kipps
Journal:  J Exp Med       Date:  1994-03-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.